Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein
Fig 5
Repeat mAbs do not potentiate the SPZ neutralization of C-CSP mAbs in vivo.
(A) Liver burden in mice (n = 5/group; line indicates geometric mean) 40 hours post-challenge mediated by indicated mAb combinations (mAb10, 100 μg; C-CSP mAbs or VRC01, 300 μg) administered 2 hours before IV challenge with 2,000 Pb-PfCSP-SPZ. (B) Liver burden (top) and parasitemia (bottom) in mice (n = 5-10/group) respectively 40 hours and 5 days post-challenge mediated by indicated mAb combinations (mAb10, 50 μg in left experiment, 30 μg in right experiment; C-CSP mAbs or VRC01, 300 μg) administered 24 hours before ID challenge with 5,000 Pb-PfCSP-SPZ. (A-B): P-values were determined by comparing C-CSP mAb + mAb10 (orange/purple squares) to mAb10 + VRC01 (purple squares) using either the two-tailed Mann-Whitney test (2 comparisons) or the Kruskal-Wallis test with Dunn’s post-hoc correction (>2 comparisons). Purple dotted lines were set at mAb10 + VRC01; vertical lines separate independent experiments. (C) MFI of Pb-PfCSP-SPZ (filled squares) and PfSPZ (open squares) bound by 2 μg/mL mAb10-A750 when co-incubated with 100 μg/mL of specified unlabeled mAb. P-values were determined by comparing PfCSP mAbs to VRC01 using the Kruskal-Wallis test. (A-C): ***, p<0.001; **, p<0.01; *, p<0.05; ns (not significant), p>0.05.